ARKG vs BIL

ARK Genomic Revolution ETF vs SPDR Bloomberg 1-3 Month T-Bill ETF

Quick take
  • • BIL has the lower expense ratio at 0.14% vs 0.75% for ARKG.
  • • BIL pays a higher dividend yield (3.66%).

Side-by-side metrics

MetricARKGBIL
Expense ratio
Annual fee. Lower is better.
0.75%0.14%
Dividend yield
Trailing 12-month yield.
0.00%3.66%
AUM
Assets under management — bigger funds are typically more liquid.
$2.21B$48.51B
YTD return
66.55%3.12%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.110.00
P/E ratio
——
Last price
$47.17$91.50
Inception
——
Issuer
ARKState Street

ARKG top holdings

Top holdings · ARKG
TWSTTwist Bioscience Corp8.75%
TXG10x Genomics Inc Ordinary Shares - Class A8.73%
TEMTempus AI Inc Class A common stock8.36%
ABSIAbsci Corp5.56%
CRSPCRISPR Therapeutics AG5.22%
GHGuardant Health Inc4.88%
NTRANatera Inc4.71%
ILMNIllumina Inc4.69%
LLYEli Lilly and Co3.92%
BEAMBeam Therapeutics Inc3.69%
Sector breakdown · ARKG
Healthcare100.0%

BIL top holdings

Holdings data unavailable for BIL.

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $2.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 8.7% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About BIL

BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) is Ultra-short T-Bills, cash-equivalent. Managed by State Street, the fund carries $48.5B in assets under management, an expense ratio of 0.14%, a dividend yield of 3.66%.